Research Roundup


The latest research news relevant to pharmacy, put together by Debbie Rigby

Pioglitazone use and risk of bladder cancer

A population based cohort study of 145 806 patients newly treated with antidiabetic drugs indicates that pioglitazone is associated with an increased risk of bladder cancer. Pioglitazone was associated with an overall 63% increased risk of incident bladder cancer and varied in a duration dependent and dose dependent fashion.. The absence of an association with rosiglitazone suggests that the increased risk is drug specific and not a class effect.

BMJ 2016;352:i1541.

Medscape summary

 

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

The combination of rosuvastatin (10 mg per day), candesartan (16 mg per day), and hydrochlorothiazide (12.5 mg per day) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease. The number needed to treat for 5.6 years to prevent one event death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke was 72.

New Engl J Med, first published on April 2, 2016.

Editorial

 

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Therapy with candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day was not associated with a lower rate of major cardiovascular events than placebo among persons at intermediate risk who did not have cardiovascular disease. The trial included men 55 years of age or older and women 65 years of age or older who had at least one cardiovascular risk factors.

New Engl J Med, first published on April 2, 2016.

 

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group, with a 24% reduction in death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

 

New Engl J Med, first published on April 2, 2016.

 

Previous Can anyone identify these mystery objects?
Next Treat sugar addiction like nicotine: study

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.